Peptide and compounding law · Updated
Is ipamorelin legal?
Ipamorelin is not an FDA-approved drug, and it is on neither the 503A nor the 503B bulks list. In August 2024 the FDA said neither ipamorelin nor its acetate has a USP or NF monograph or is a component of an approved drug. For 503A pharmacies, the FDA lists ipamorelin acetate among nominations that were withdrawn, which leaves it in no 503A interim-policy category, and in 2024 the FDA proposed not adding ipamorelin to the 503A list. For 503B outsourcing facilities, the FDA has listed ipamorelin acetate in Category 2, "Bulk Drug Substances that Raise Significant Safety Risks", since September 29, 2023. HHS's draft peptide policy of October 30, 2026 covers only 503A compounding, so, in our reading, it leaves the 503B position unchanged. In August 2026 the FDA called one North Carolina seller's "Tesamorelin Ipamorelin Blend", labeled for research use, an unapproved new drug.
| List | Ipamorelin's status | List's date | Source |
|---|---|---|---|
| FDA-approved drugs | No match in openFDA's Drugs@FDA data (openFDA says to "assume all results are unvalidated") | Drugs@FDA data updated November 16, 2026 | openFDA, Drugs@FDA data |
| USP or NF monograph | None, for ipamorelin or ipamorelin acetate | FDA memo of August 19, 2024 | FDA briefing, PDF p. 6 |
| 503A bulks list (21 CFR 216.23) | Not listed. The list has six substances, none a peptide | 84 FR 4710 (February 19, 2019) | eCFR |
| 503A Categories 1, 2 and 3 | Not in any category | Updated May 14, 2026 | FDA 503A list |
| FDA's "nominated but withdrawn" table | Ipamorelin acetate is listed | Page current as of April 22, 2026 | FDA safety-risk page |
| 503B bulks list | Not listed. The list has five substances, none a peptide | Current as of May 16, 2024 | FDA 503B bulks list |
| 503B Category 2 | Ipamorelin acetate, added September 29, 2023 | 503B list updated March 21, 2025 | FDA 503B list; FDA safety-risk page |
| HHS draft peptide policy | Covers 503A compounding with the peptides in its Appendix A; the notice does not mention 503B | Published October 30, 2026; comments closed November 13, 2026 | 91 FR 68526 |
| Date | What happened | Source |
|---|---|---|
| April 1, 2020 | FDA warning letter to a Kentucky compounder names ipamorelin among bulk drug substances whose compounded products are "not eligible" for the 503A exemptions | FDA warning letter |
| September 29, 2023 | FDA places ipamorelin acetate in 503B Category 2 | FDA safety-risk page |
| August 19, 2024 | FDA staff memo: the criteria "weigh against" listing; FDA proposes not adding ipamorelin or ipamorelin acetate to the 503A list | FDA briefing, PDF pp. 6, 43 |
| October 29, 2024 | The Pharmacy Compounding Advisory Committee votes against listing each form: 0 yes, 12 no, 1 abstention, on each vote | Minutes, approved January 15, 2025 |
| January 7, 2025 | FDA stops placing newly nominated substances into 503A or 503B categories | FDA 503A page; 503B guidance |
| August 24, 2026 | FDA warning letter to a Cornelius, NC seller of "research" peptides treats its "Tesamorelin Ipamorelin Blend" as an unapproved new drug | FDA warning letter |
| October 30, 2026 | HHS gives notice of a draft enforcement-discretion policy for certain peptides in 503A compounding; the notice does not mention 503B | 91 FR 68526 |
What ipamorelin is, in the FDA's words
The FDA's 2024 evaluation calls ipamorelin (free base) "a five amino acids peptide containing unnatural amino acids" and says both forms "act as growth hormone secretagogues (GHSs)" (FDA briefing, PDF pp. 22, 40). It also says that compounded formulations of ipamorelin "are increasingly being marketed by medical spas and wellness clinics" (PDF p. 20).
The form matters. "Ipamorelin acetate and ipamorelin (free base) are different BDSs" (bulk drug substances), the FDA says, and the two nominations it received were unclear about which one they meant (PDF p. 6). Its 503B Category 2 and withdrawn-table entries both name ipamorelin acetate. In our reading, a certificate of analysis, a prescription and a supply agreement should all name the same form.
Why a 503A pharmacy has no listed route for ipamorelin
A 503A pharmacy, compounding for an identified patient on a valid prescription, may use a bulk ingredient only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug, or is on the 503A bulks list (21 U.S.C. 353a). Ipamorelin meets none of the three. In the FDA's words, "There is no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph for ipamorelin (free base) or its acetate form, and neither is a component of an FDA-approved drug" (PDF p. 6). The list at 21 CFR 216.23 has six substances, none a peptide. An FDA warning letter of April 1, 2020 to a Kentucky compounder already named ipamorelin among bulk substances that "do not appear on the 503A bulks list" (FDA warning letter).
Only for Category 1 does the FDA say it "does not intend to take action against a compounder" (FDA 503A page). Ipamorelin is in none of the three 503A categories on the list updated May 14, 2026 (FDA 503A list). The FDA's safety-risk page instead lists ipamorelin acetate among substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators" (FDA safety-risk page). In our reading, that leaves a pharmacy no interim-policy route.
In 2024 the FDA evaluated both forms "on its own initiative", for growth hormone deficiency and postoperative ileus (PDF p. 6). Its staff memo of August 19, 2024 found that the criteria "weigh against" listing and proposed "not adding ipamorelin acetate or ipamorelin (free base) to the 503A Bulks List" (PDF pp. 6, 43). On October 29, 2024 the Pharmacy Compounding Advisory Committee voted on each form, and both votes were 0 yes, 12 no and 1 abstention (minutes). A committee vote is advice; the list changes only by regulation, and we found no proposed or final rule on ipamorelin in the Federal Register as of November 17, 2026.
The 503B side: Category 2 since September 29, 2023
An outsourcing facility may compound from a bulk ingredient only if it is on the FDA's list of substances for which there is a "clinical need" or the drug is on the FDA's shortage list (21 U.S.C. 353b). The 503B bulks list has five substances, none a peptide. For Category 2 substances, the FDA says it "would consider taking action against an outsourcing facility" (FDA 503B page).
The FDA's 503B category list, updated March 21, 2025, puts "Ipamorelin Acetate" under "503B Category 2: Bulk Drug Substances that Raise Significant Safety Risks" (FDA 503B list), and the safety-risk page dates the placement September 29, 2023. In the FDA's words, compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration", a published study "identified serious adverse events including death when ipamorelin was administered intravenously", and for "certain other injectable routes of administration" the agency "lacks sufficient information to know whether the drug would cause harm" (FDA safety-risk page). It is the only substance in the FDA's withdrawn table that is still in Category 2. Is TB-500 legal? and Is MOTS-c legal? cover two withdrawn-table peptides without that entry.
This is the side that matters for office stock: outsourcing facilities, the FDA explains, "can distribute compounded drug products to health care practitioners or health care facilities without first receiving a prescription for an identified individual patient" (503B guidance, January 2025, p. 8, note 19). And since the FDA no longer categorizes substances nominated on or after January 7, 2025, a fresh nomination would not, in our reading, move ipamorelin into Category 1. See 503A vs 503B.
What the October 30, 2026 HHS draft policy does and does not do
On October 30, 2026, HHS, not the FDA, gave notice of a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (91 FR 68526). HHS says it does not intend to take enforcement action against "a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A." The notice itself names no peptide; it points readers to an hhs.gov address "to find the most current version of the policy". The FDA's peptide lists shows which peptides Appendix A names.
Two limits apply whatever the appendix says. The notice describes a policy for 503A compounding by state-licensed pharmacies, federal facilities and licensed physicians and does not mention 503B, so, in our reading, it does not move ipamorelin out of 503B Category 2. And it is a draft that the notice says "is not binding on HHS or the public". Comments closed on November 13, 2026 (regulations.gov), and we found no final version in the Federal Register as of November 17, 2026.
"Research use only" ipamorelin, including a North Carolina case
Labeling is not the only evidence of intended use: intent may also be shown "by the circumstances surrounding the distribution of the article" (21 CFR 201.128). On August 24, 2026 the FDA wrote to a Cornelius, North Carolina seller whose products included a "Tesamorelin Ipamorelin Blend". Despite labeling "for laboratory, research, and analytical use", the FDA said, "evidence obtained from your website establishes that your products are intended to be drugs for human use", and "these products are unapproved new drugs" (FDA warning letter).
An NDC number on a supplier's paperwork does not change that. The NDC data on openFDA (unvalidated, openFDA says) show only bulk-ingredient listings for ipamorelin, none a finished drug (openFDA NDC data, updated November 16, 2026), and assignment of an NDC "does not denote approval of the establishment or the drug" (21 CFR 207.77). More in Research-use-only peptides.
North Carolina and next steps
In North Carolina, the Board of Pharmacy allows a pharmacy to dispense a compounded drug "only pursuant to a prescription that is valid", bars offering compounded preparations "to other entities for resale", and requires office-use compounding to "comply with applicable federal law" (21 NCAC 46 .2801). In our reading, the FDA's lists give a North Carolina clinic no ipamorelin route today. If you offer it, or are being asked to, see peptide law for clinics and pharmacies.
Common questions
Is ipamorelin FDA-approved?
No. In August 2024 the FDA said neither ipamorelin nor ipamorelin acetate is a component of an FDA-approved drug, and openFDA's Drugs@FDA data (updated November 16, 2026; unvalidated, openFDA says) show no match. An NDC number on a bulk ingredient is not an approval.
Can a compounding pharmacy make ipamorelin for a patient?
In our reading, not through any route on the FDA's lists. Ipamorelin is not on the 503A bulks list and is in no 503A interim category, and in 2024 the FDA proposed against listing it. HHS's October 30, 2026 draft covers only the peptides in its Appendix A; read that appendix, with its date, before relying on it.
Can a med spa keep ipamorelin as office stock?
In our reading, office stock is the 503B side, since outsourcing facilities can distribute without a patient-specific prescription. The FDA has listed ipamorelin acetate in 503B Category 2 since September 29, 2023, and for Category 2 substances says it "would consider taking action against an outsourcing facility". The HHS draft's enforcement statement names only state-licensed pharmacies, federal facilities and licensed physicians.
Are ipamorelin and ipamorelin acetate the same thing?
Not to the FDA. It treats the free base and the acetate salt as different bulk drug substances and evaluated both in 2024. Its 503B Category 2 and withdrawn-table entries name ipamorelin acetate.
Is it legal to buy ipamorelin online as a research peptide?
On August 24, 2026 the FDA told a Cornelius, North Carolina seller that, despite labeling "for laboratory, research, and analytical use", its products, including a "Tesamorelin Ipamorelin Blend", were "intended to be drugs for human use" and were "unapproved new drugs". The HHS draft covers compounding by state-licensed pharmacies, federal facilities and licensed physicians; it says nothing about products sold for research.
Update log
- November 17, 2026. Published. Read at the source November 17, 2026: the FDA's 503A category list (May 14, 2026), 503B category list (March 21, 2025), safety-risk page (April 22, 2026), 503A and 503B pages, 503B bulks list (May 16, 2024) and 503B interim policy guidance; 21 CFR 216.23, 201.128 and 207.77; 21 U.S.C. 353a and 353b; the FDA's 2024 ipamorelin briefing and committee minutes; the HHS notice (91 FR 68526) and its regulations.gov docket; two FDA warning letters; openFDA data (November 16, 2026); and 21 NCAC 46 .2801. hhs.gov could not be read by automated tools, so nothing on this page rests on it.
Sources
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list, updated May 14, 2026)
- FDA, Bulk Drug Substances Used in Compounding Under Section 503A (current as of May 14, 2026)
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (current as of April 22, 2026)
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (category list, updated March 21, 2025)
- FDA, Bulk Drug Substances Used in Compounding Under Section 503B (current as of January 7, 2025)
- FDA, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B, guidance for industry (January 2025)
- FDA, 503B Bulk Drug Substances List (current as of May 16, 2024)
- FDA, Evaluation of Ipamorelin-related Bulk Drug Substances, briefing for the Pharmacy Compounding Advisory Committee (memo dated August 19, 2024; page numbers are PDF pages)
- FDA, Final Summary Minutes of the Pharmacy Compounding Advisory Committee, October 29, 2024 (approved January 15, 2025)
- FDA, October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee (meeting page)
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (Oct. 30, 2026)
- Regulations.gov, docket HHS-OASH-2026-0496 (comment period ended November 13, 2026)
- 21 U.S.C. 353a (section 503A)
- 21 U.S.C. 353b (section 503B)
- 21 CFR 216.23 (503A bulks list)
- 21 CFR 201.128 (intended use)
- 21 CFR 207.77 (legal status of registration, listing and NDC)
- FDA warning letter, Tailor Made Compounding LLC, Nicholasville, KY (April 1, 2020)
- FDA warning letter, August 24, 2026 (Cornelius, NC peptide seller)
- openFDA, Drugs@FDA data searched for ipamorelin (no match; data updated November 16, 2026; openFDA results are unvalidated)
- openFDA, NDC directory data for ipamorelin (bulk-ingredient listings only; data updated November 16, 2026; openFDA results are unvalidated)
- 21 NCAC 46 .2801 (North Carolina compounding rule; Cornell LII copy)
Related
Offering ipamorelin, or being asked to?
DPS Law advises clinics, physicians and pharmacies on North Carolina and federal compounding law. For another state's pharmacy or medical board rules, talk to a lawyer licensed in that state. Our attorney is licensed in North Carolina only.